Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database

Hira S Mian, MD, Christine Eisfeld, Christopher P. Venner, MD, Victor Jimenez-Zepeda, MD, Cyrus Khandanpour, MD, Arleigh McCurdy, MD BSc, Michael Sebag, MD PhD FRCPC, Kevin W Song, MD FRCPC, Richard Leblanc, MD FRCPC, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Darrell J White, MD, Julie Stakiw, MD, Anthony Reiman, MD, Martha L Louzada, MDMSc, Muhammad Aslam, MD, Rami Kotb, MD, Engin Gul, BS, MBA, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-133372

Published: 2020

Journal Articles

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Arleigh McCurdy, MD BSc, Christopher P. Venner, MD, Martha L Louzada, MDMSc, Richard LeBlanc, MD FRCPC, Michael Sebag, MD PhD FRCPC, Kevin W Song, MD FRCPC, Victor Jimenez-Zepeda, MD, Rami Kotb, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Hira S Mian, MD, Darrell J White, MD, Julie Stakiw, MD, Muhammad Aslam, MD, Anthony Reiman, MD, Engin Gul, BSc, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-142800

Published: 2020

Journal Articles

Treatment of Multiple Myeloma Patients Progressing on Lenalidomide-Based Regimens

Donna E Reece, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD, Kevin Song, MD, Michael Sebag, MD PhD, Richard Leblanc, MDFRCPC, Martha L Louzada, MDMSc, Darrell J White, MD, Julie Stakiw, MD, Tony Reiman, MD, Rami Kotb, MD, Muhammad Aslam, MD, Engin Gul, BS, MBA, Christopher P Venner, MD

Blood (2019) 134 (Supplement_1): 1886.

https://doi.org/10.1182/blood-2019-125479

Published: 2019

Journal Articles

Treatment of Myeloma Patients Progressing on Lenalidomide-Based Maintenance after ASCT Performed As Part of 1 st , 2 nd or 3 rd Line Therapy: Real-World Results from the National Myeloma Canada Research Network (MCRN) Database

Donna E Reece, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD, Kevin Song, MD, Richard Leblanc, MDFRCPC, Michael Sebag, MD PhD, Darrell J White, MD, Hannah Cherniawsky, BSc,MD, Tony Reiman, MD, Julie Stakiw, MD, Martha L Louzada, MDMSc, Rami Kotb, MD, Muhammad Aslam, MD, Engin Gul, BS, MBA, Christopher P Venner, MD

Blood (2019) 134 (Supplement_1): 3173.

https://doi.org/10.1182/blood-2019-125810

Published: 2019

Journal Articles

Transfusion Practice Following Intracranial Hemorrhage in Acute Leukemia: An Institutional Review

Shannon Nixon, NP, Dawn Maze, MD FRCPC, MSc, Eshetu G Atenafu, MSc, P.Stat, Danielle Brandys, MN NP, Cindy Susan Murray, MN NP, Suzanne Rowland, MSN NP, Mary Clementine Doherty, MN NP, Amanda Wolfe, BScPharm, RPh, ACPR, Benjamin YM Kwan, MD FRCPC, Eugene Yu, MD FRCPC, Breanne Lechner, BSc, MDc), Lani Lieberman, MD FRCPC

Blood (2018) 132 (Supplement 1): 4740.

https://doi.org/10.1182/blood-2018-99-112718

Published: 2018

Journal Articles

Comparison of the Impact of Pre-Transplant Co-Morbidity Scores on Allogeneic Hematopoietic Stem Cell Transplant Outcomes

Mohammed A. Marei, Eshetu G Atenafu, MSc, P.Stat, Arjun Law, MD DM, Wilson Lam, MD, Rajat Kumar, MD, Santhosh Thyagu, MD DM, Auro Viswabandya, MD DM, Dennis Dong Hwan Kim, MD, Jeff H. Lipton, MD PhD, Hans A. Messner, MD PhD, Fotios V. Michelis, MD PhD

Blood (2018) 132 (Supplement 1): 4670.

https://doi.org/10.1182/blood-2018-99-113884

Published: 2018

Journal Articles

Real-World Outcomes with Bortezomib-Containing Regimens and Lenalidomide Plus Dexamethasone for the Treatment of Transplant Ineligible MM Patients: A Multi-Institutional Report from the National Myeloma Canada Research Network (MCRN) Database

Victor Jimenez-Zepeda, MD, Donna E Reece, MD, McCurdy R Arleigh, MD MHA, FRCPC, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Michael Sebag, MD PhD, Julie Stakiw, MD FRCPC, Kevin Song, MD, Richard Leblanc, MDFRCPC, Tony Reiman, MD, Martha L Louzada, MD, Rami Kotb, MD, Engin Gul, BSc, Christopher P. Venner, MD FRCPC

Blood (2018) 132 (Supplement 1): 2008.

https://doi.org/10.1182/blood-2018-99-117363

Published: 2018

Journal Articles

Cognitive Outcomes Among Patients with Hematological Cancer with Access to Computerized Cognitive Training: Results from a Feasibility Study

Samantha J Mayo, RN PhD, Eshetu G Atenafu, MSc, P.Stat, Sean B Rourke, PhD, John Kuruvilla, MD, Christine I Chen, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 3454.

https://doi.org/10.1182/blood.V130.Suppl_1.3454.3454

Published: 2017

Journal Articles

Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting

Julie Cote, MD, Madeline Phillips, Eshetu G Atenafu, MSc, PStat, Esther Masih-Khan, PhD, Donna Reece, MD, Christine Chen, MD, Anca Prica, MD, Rodger Tiedemann, MD PhD, Suzanne Trudel, MD, Vishal Kukreti, MD

Blood (2016) 128 (22): 2137.

https://doi.org/10.1182/blood.V128.22.2137.2137

Published: 2016

Journal Articles

IKZF1/3 Protein Expressions Are Associated with a Better Survival in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide

Maryam Pourabdollah, MD, Mohammad Bahmanyar, MD, Eshetu G Atenafu, MSc, PStat, Donna Reece, MD, Hong Chang, MD PhD

Blood (2016) 128 (22): 4506.

https://doi.org/10.1182/blood.V128.22.4506.4506

Published: 2016

Journal Articles

Outcome of 17p Deleted Multiple Myeloma (MM) in the Era of Novel Agents and Tandem Transplantation: A Single Centre Experience

Gurdeep Parmar, MDFRACP, Esther Masih-khan, PhD, Eshetu G Atenafu, MSc, Donna E. Reece, MD, Suzanne Trudel, MD, Rodger E. Tiedemann, MD PhD, Vishal Kukreti, MD, Christine I. Chen, MD MD FRCPC

Blood (2014) 124 (21): 4756.

https://doi.org/10.1182/blood.V124.21.4756.4756

Published: 2014

Journal Articles

Evidence of Effect Modification of Graft-Versus-Leukemia Effect of Cytomegalovirus By Alemtuzumab in Myeloid Malignancies Undergoing Unrelated Donor Transplantation

Mohamed Shanavas, MD FRACP, FRCPA, Jieun Uhm, MD, Naheed Alam, MBBS,MD, Eshetu G Atenafu, MSc, John Kuruvilla, MD FRCPC, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Matthew Seftel, MRCP, FRCPC, MPH, Vikas Gupta, MD MRCP, FRCPath, Dennis Kim, MD PhD

Blood (2014) 124 (21): 5927.

https://doi.org/10.1182/blood.V124.21.5927.5927

Published: 2014

Journal Articles

A Comparison Of Long-Term Outcomes Of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors In CML Patients Relapsed After Allogeneic Hemopoietic Stem Cell Transplantation

Mohamed Shanavas, MD, FRACP, FRCPA, Hans A. Messner, MD, PhD, Suzanne Kamel-Reid, PhD, Eshetu G Atenafu, MSc, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, FRCPC, Dennis Dong Hwan Kim, MD, PhD, Jieun Uhm, MD, Anna Lambie, NP, Laura Ellis, NP, MN, RN (EC), Jeffrey H. Lipton, MD, PhD

Blood (2013) 122 (21): 5501.

https://doi.org/10.1182/blood.V122.21.5501.5501

Published: 2013

Journal Articles

Anticoagulation Prophylaxis With Enoxaparin For Patients With Acute Lymphoblastic Leukemia Receiving Asparaginase-Based Intensification Therapy

Hassan Sibai, Jack T Seki, PharmD, Eshetu G Atenafu, MSc, Karen W.L. Yee, MD, FRCP, Andre C Schuh, MD, Vikas Gupta, MD, FRCP, FRCPath, Mark D. Minden, MD, PhD, Aaron D. Schimmer, MD, PhD, Joseph M. Brandwein, MD

Blood (2013) 122 (21): 2636.

https://doi.org/10.1182/blood.V122.21.2636.2636

Published: 2013

Journal Articles

Risk Model Incorporating Donor IL6 and ifng Genotype and Gut Gvhd Can Discriminate High Risk Patients For Steroid Refractory Acute Gvhd

Naheed Alam, MBBS, Eshetu G Atenafu, MSc, Wei Xu, Ph.D., Jieun Uhm, MD, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, Hans A. Messner, MD, PhD, Jeffrey H. Lipton, MD, PhD, Dennis Kim, MD, PhD

Blood (2013) 122 (21): 4613.

https://doi.org/10.1182/blood.V122.21.4613.4613

Published: 2013

Journal Articles

Quality of Life Following Completion of Treatment for Adult Acute Lymphoblastic Leukemia with a Pediatric-Based Protocol.

Elena Liew, MD, Eshetu G Atenafu, MSc, Shabbir M.H. Alibhai, MD, Joseph M. Brandwein, MD

Blood (2012) 120 (21): 2567.

https://doi.org/10.1182/blood.V120.21.2567.2567

Published: 2012

Journal Articles

The Benefit of Allogeneic Hematopoietic Cell Transplantation in Older Patients with Acute Myeloid Leukemia Is Restricted to Those in First Complete Remission At the Time of Transplantation.

Fotios V. Michelis, MD, PhD, Hans A. Messner, MD, PhD, Eshetu G Atenafu, MSc, Dennis Dong Hwan Kim, MD, PhD, John Kuruvilla, MD, FRCPC, Jeffrey H. Lipton, MD, PhD, Jieun Uhm, MD, David Loach, MD, Vikas Gupta, MD, FRCP, FRCPath

Blood (2012) 120 (21): 3097.

https://doi.org/10.1182/blood.V120.21.3097.3097

Published: 2012

Journal Articles

CMV Reactivations and Their Impact On Outcomes in Patients After Hematopoietic Cell Transplantation

Naheed Alam, MBBS, Anna Lambie, NP, Yvette Neme Yunes, MD, Feras Alfraih, MD, Eshetu G Atenafu, MSc, Dennis Dong Hwan Kim, MD, PhD, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, Jeff H Lipton, MD, Hans A. Messner, M.D./Ph.D

Blood (2012) 120 (21): 4501.

https://doi.org/10.1182/blood.V120.21.4501.4501

Published: 2012

NARROW

Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Treatment of Multiple Myeloma Patients Progressing on Lenalidomide-Based Regimens

Treatment of Myeloma Patients Progressing on Lenalidomide-Based Maintenance after ASCT Performed As Part of 1 st , 2 nd or 3 rd Line Therapy: Real-World Results from the National Myeloma Canada Research Network (MCRN) Database

Transfusion Practice Following Intracranial Hemorrhage in Acute Leukemia: An Institutional Review

Comparison of the Impact of Pre-Transplant Co-Morbidity Scores on Allogeneic Hematopoietic Stem Cell Transplant Outcomes

Real-World Outcomes with Bortezomib-Containing Regimens and Lenalidomide Plus Dexamethasone for the Treatment of Transplant Ineligible MM Patients: A Multi-Institutional Report from the National Myeloma Canada Research Network (MCRN) Database

Cognitive Outcomes Among Patients with Hematological Cancer with Access to Computerized Cognitive Training: Results from a Feasibility Study

Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting

IKZF1/3 Protein Expressions Are Associated with a Better Survival in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide

Outcome of 17p Deleted Multiple Myeloma (MM) in the Era of Novel Agents and Tandem Transplantation: A Single Centre Experience

Evidence of Effect Modification of Graft-Versus-Leukemia Effect of Cytomegalovirus By Alemtuzumab in Myeloid Malignancies Undergoing Unrelated Donor Transplantation

A Comparison Of Long-Term Outcomes Of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors In CML Patients Relapsed After Allogeneic Hemopoietic Stem Cell Transplantation

Anticoagulation Prophylaxis With Enoxaparin For Patients With Acute Lymphoblastic Leukemia Receiving Asparaginase-Based Intensification Therapy

Risk Model Incorporating Donor IL6 and ifng Genotype and Gut Gvhd Can Discriminate High Risk Patients For Steroid Refractory Acute Gvhd

Quality of Life Following Completion of Treatment for Adult Acute Lymphoblastic Leukemia with a Pediatric-Based Protocol.

The Benefit of Allogeneic Hematopoietic Cell Transplantation in Older Patients with Acute Myeloid Leukemia Is Restricted to Those in First Complete Remission At the Time of Transplantation.

CMV Reactivations and Their Impact On Outcomes in Patients After Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only